Canaccord Genuity Reiterates Buy Rating on ACADIA Pharmaceuticals Inc. (ACAD)

Market Context

ACADIA Pharmaceuticals Inc. operates in the Healthcare sector. The stock currently trades at $25.20 with a market capitalization of $4.2B.

Analyst coverage from Canaccord Genuity provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for ACADIA Pharmaceuticals Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for ACADIA Pharmaceuticals Inc.

Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jun 29, 2026	Canaccord Genuity	Buy	N/A
Jun 29, 2026	Citigroup	Buy	N/A
May 08, 2026	Citigroup	Buy	N/A
Mar 25, 2026	B of A Securities	Buy	N/A
Mar 04, 2026	JP Morgan	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View ACAD Stock Page